POS-380 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATHY (THE ALIGN STUDY)

• H. Lambers Heerspink,
• D. Kohan,
• R. Lafayette,
• A. Levin,
• H. Zhang,
• A. Glicklich,
• A. King,
• M. Camargo,
• J. Barratt

Affiliations

H. Lambers Heerspink

University medical Center Groningen, Clinical Pharmacy and Pharmacology, Groningen Groningen, Netherlands

D. Kohan

University of Utah Health Science Center, Division of Nephrology, Salt Lake City, United States

R. Lafayette

Stanford University School of Medicine, Division of Nephrology, Stanford, United States

A. Levin

University of Britsh Columbia, Division of Nephrology, Vancouver, Canada

H. Zhang

Peking University First Hospital, Renal Division, Beijing, China

A. Glicklich

Chinook Therapeutics, Clinical Development, Seattle, United States

A. King

Chinook Therapeutics, Renal Discovery and Translational Medicine, Seattle, United States

M. Camargo

Chinook Therapeutics, Clinical Development, Seattle, United States

J. Barratt

University of Leicester, Department of Respiratory Sciences, Leicester, United Kingdom